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Members of the paired box (Pax) gene family are expressed in distinctive regions 
of the developing central nervous system, supporting a role of neural patterning. 
In this study, Pax2 protein expression was examined in the developing neural 
tube by immunohistochemistry methods in 30 human embryos of Carnegie 
stages (CS) 10–20 collected after legal abortions. Pax2 expression was detected 
along the boundaries of main divisions of the developing brain and spinal cord. 
However, Pax2 expression was found to be stronger in the developing brain than 
in the spinal cord of the same young embryos in CS 10–14, which was the most 
remarkable at CS 10. Pax2 expression was detected in the developing forebrain, 
midbrain and hindbrain. At later stages (CS 16–20) Pax2 expression was observed 
in the midbrain-hindbrain boundary and also in the developing diencephalon and 
cerebellum. In the wall of developing spinal cord Pax2 expression was detected 
in the ventricular, mantel and marginal layers. Pax2 staining was seen to increase 
throughout the later stages of spinal cord development and significantly stronger 
expression was found at CS 16–20 compared to CS 10. Furthermore, spatially 
restricted expression of Pax2 was observed along the compartmental dorsal-ventral 
axis of the spinal cord as Pax2 staining was weaker in the ventricular layer of the 
ventral part of the developing spinal cord compared with developing area of 
dorsal part. (Folia Morphol 2014; 73, 3: 272–278)
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INTRODUCTION
The family of paired box (Pax) genes constitutes 
a group of developmental genes with a highly con-
served paired domain, which encode nuclear trans-
cription factors [24]. Evidence from mice and human 
embryos indicates that Pax genes play an important 
role in early mammalian embryogenesis. Furthermore, 
the members of the Pax genes family have been shown 
to play critical roles in the formation of the nervous 
system as the restricted expression pattern along the 
craniocaudal and dorsoventral axes of the neural tube 
during early embryogenesis has demonstrated [21].
The Pax gene family consists of 9 members divided 
into subgroups based on various aspects of similarity: 
subgroup I includes Pax1 and Pax9; subgroup II inclu-
des Pax2, Pax5 and Pax8; subgroup III includes Pax3 
and Pax7; subgroup IV includes Pax4 and Pax6 [21]. 
Except for Pax1 and Pax9, all Pax genes are spatially 
and temporally expressed during the development of 
the central nervous system [24]. At early developmen-
tal stages, Pax3, Pax6 and Pax7 are expressed in almost 
the entire developing neural tube, only Pax6 is exclu-
ded from the mesencephalic roof [24]. In later stages, 
the expression of Pax3/Pax7 is retracted with a rostral 
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limit at the level of posterior commissure, while Pax6 
expression in the forebrain persists during embryo-
genesis and even in certain structures in adulthood 
[17]. For the second group of late expressed Pax genes 
(Pax2, Pax5, Pax8), the midbrain-hindbrain boundary 
is believed to be the rostral limit [10, 16, 24]. Several 
animal studies have revealed the importance of Pax2 
gene in the establishment and maintenance of the 
midbrain/hindbrain organiser region, which has been 
shown to control the development of the midbrain 
and cerebellum [1, 14, 23]. 
Despite numerous investigations on Pax genes in 
animals, only limited results exist about the deve-
lopmental role of human Pax3 and Pax6 genes [5, 20], 
while the data about Pax2 genes in the human nervous 
system formation are very scanty [18, 19]. Therefore, 
the aim of this study was to determine the temporal 
and spatial expression of Pax2 protein during the early 
stages (Carnegie stages [CS] 10–20) of spinal cord and 
brain development in human embryos. The period from 
CS 10 (approximately 22–23 days of development) to 
CS 20 (approximately 51–53 days of development) 
is critical, as during that time all important changes 
take place in the size, shape and complexity of the 
developing brain and spinal cord [11]. 
MATERIALS AND METHODS
The morphological study was performed on 30 hu- 
man embryos at CS 10–20. The human embryos 
were obtained by medical abortions in Tartu Univer-
sity Hospital. The study was approved by the Ethics 
Review Committee on Human Research of the Uni-
versity of Tartu (no 183/M-40, issued on 29.06.2009). 
The embryos were fixed in 4% paraformaldehyde 
and embedded in paraffin according to standard 
methods. Tissue blocks were cut serially in trans-
versal direction with microtome Ergostar HM-200 
(Microm, Germany). The embryos were classified 
by CS [11] and examined using an Olympus BX-50 
microscope. Specimens for light microscopy were 
stained using the haematoxylin and eosin for ge-
neral orientation to sections. Slides were observed 
and photographed by a Zeiss Axiophot 2 microscope 
(Zeiss, Germany). According to CS, the embryos were 
grouped as follows: CS 10 — 4 embryos (in total 
78 sections per CS 10), CS 12 — 4 embryos (92 sec-
tions per CS 12), CS 14 — 10 embryos (154 sections 
per CS 14), CS 16 — 6 embryos (130 sections per 
CS 16), CS 18 — 4 embryos (136 sections per CS 18), 
CS 20 — 2 embryos (73 sections per CS 20). 
Immunohistochemistry
Three-µm thick paraffin sections mounted on Super-
Frost slides (Menzel-Gläser, Germany) were deparaffini-
sed and rehydrated. Peroxidase activity was blocked by 
0.6% H2O2 (Fluka, France) in methanol. Sections were 
washed in PBS (pH = 7.4) and after that in distilled wa-
ter (3 × 2 min). The slides were irradiated with 0.001 M 
citrate buffer (pH = 6.0) for 10 min using a microwave 
oven (Daewoo, model No KOG-840P) at 98ºC. The slides 
were treated with normal 1.5% goat serum (Gibco, 
Invitrogen, USA) for 30 min at room temperature and 
incubated with the primary antibody Pax2 (4 µg/mL 
dilution in 0.1 M PBS, abcam, UK) overnight at 4°C in 
a humidity chamber. The primary antibody used was 
rabbit polyclonal antibody to Pax2 (abcam, ab23799), 
which has been reported to perform excellently in im-
munohistochemical applications with paraffin embed-
ded human samples [13] as well in Western blotting 
applications with human tissue samples [6]. 
 On the next day, the sections were incubated 
with the universal secondary antibody (Vectastain 
ABC Universal Kit, Burlingame, USA) for 30 min at 
room temperature. Peroxidatic activity was detected 
with DAB (3,3’-Diaminobenzidine; Vector, USA) and 
the sections were counterstained with haematoxylin. 
The labelling was expressed by a subjective scale 
ranging from 0 to 3 (0 — no staining, 1 — weak 
staining, 2 — moderate staining, 3 — strong staining; 
Fig. 1). Immunohistochemistry negative controls were 
performed by omitting the primary antibody. The eva-
luation was performed by 2 independent observers 
in a blinded fashion. The mean of estimations was 
calculated and used for statistical analysis. The data 
were analysed by Kruskal-Wallis test (nonparametric 
ANOVA) with the level of significance set as p < 0.05. 
RESULTS
The expression of Pax2 protein was detected in the 
forming neural tube and the developing spinal cord of 
human embryos at all the studied stages of development. 
However, variations seem to exist in immunostaining 
intensity at different developmental stages (Table 1). If 
Pax2 expression in CS 10–14 was relatively weaker in 
the developing spinal cord, then stronger expression 
was found in CS 16–20. Statistically significant weaker 
expression of Pax2 was found in the embryos of CS 10 as 
compared to CS 16–20 (Table 1, Fig. 2). In the embryos 
of CS 16–20, Pax2 was detected in the ventricular (neu-
roepithelial) layer, mantle layer and also in the marginal 
layer of the developing spinal cord (Table 1, Figs. 3, 4). 
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Table 1. Expression of Pax2 in the developing spinal cord and brain
Carnegie stage 10 12 14 16 18 20
Spinal cord 1.37 ± 0.09a,b,c,d 1.61 ± 0.07 1.56 ± 0.07 1.80 ± 0.14a 1.83 ± 0.06b 1.80 ± 0.05c
Brain 2.0 ± 0.05d 1.91 ± 0.09 1.87 ± 0.06 1.87 ± 0.09 1.89 ± 0.08 1.83 ± 0.07 
Immunostaining intensity was graded as 0 (no staining), 1 (weak staining), 2 (moderate staining) or 3 (strong staining); the data are presented as mean ± SEM. Significant differences  
(p < 0.01) in staining intensity between groups are indicated with the same letters; a — Pax2 expression of the developing spinal cord in CS10 vs. Pax2 expression in the developing spi-
nal cord in CS16; b — Pax2 expression of the developing spinal cord in CS10 vs. Pax2 expression in the developing spinal cord in CS18; c — Pax2 expression of the developing spinal cord 
in CS10 vs. Pax2 expression in the developing spinal cord in CS20; d — Pax2 expression of the developing spinal cord in CS10 vs. Pax2 expression in the developing brain in CS10
Figure 1. A set of micrographs of the developing human spinal cord illustrating the criteria for evaluation of the staining intensity;  
a. 0 (no staining); b. 1 (weak staining); c. 2 (moderate staining); d. 3 (strong staining).
Figure 2. Transverse section of the spinal cord of the human 
embryo at CS 12. The arrows indicated the ventricular layer of 
the developing neural tube, where weak expression of Pax2 was 
detected.
Figure 3. Transvere sections of the spinal cord of human embryo 
at CS 18; A — ventricular layer; B — mantle layer; C — marginal 
layer, arrow indicates the anterior horn. Expression of Pax2 in the 
ventricular, mantle and marginal layers.
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Comparing Pax2 expression in the dorsal and ventral 
parts of the developing spinal cord, varying staining 
intensity was seen in the embryos of CS 14–20. Sig-
nificant expression of Pax2 in outer layers of the 
wall of the developing spinal cord on both dorsal 
and ventral parts was noted, but in the ventricular 
layer, the expression of Pax2 was more extensive in 
the dorsal part than in the ventral part of the spinal 
cord (Fig. 5a, b). 
Comparing the expression of Pax2 in the develo-
ping spinal cord and brain, more intensive immuno-
staining was noted in the developing brain at early 
stages of development, and statistically significant 
difference was found at CS 10 (Table 1). Concer-
ning the expression of Pax2 in the developing brain, 
staining was seen in the wall of 3 primary brain ve-
sicles: in the forebrain, midbrain and hindbrain (Figs. 
6a–c). Expression of Pax2 was also detected at the 
junction of the caudal midbrain and the rostral hin-
brain in the developing brain — strong Pax2 staining 
was seen in the region of the isthmus at later stages, 
CS 16–20 (Fig. 7). Expression of Pax2 was found also 
in the developing diencephalon: staining was noted 
in the outer regions of the dorsal (alar) plates and, as 
a thin strip, in the ventral part of the diencephalon (Fig. 8). 
Furthermore, Pax2 expression was detected in the 
ventricular, mantle and marginal layers of the develo-
ping cerebellum in the embryos of CS 18–20 (Fig. 8b).
DISCUSSION
In this study, Pax2 protein immunostaining was 
analysed in the developing nervous system in hu-
man embryos at CS 10–20. The results of the study 
demonstrated a spatially and temporally restricted 
expression pattern of Pax2 in the developing spinal 
cord and brain. 
In the early stages of development (CS 10–14), 
the forming spinal cord and brain vesicles consist of 
neuroepithelial cells, which extend over the entire 
thickness of the wall and divide rapidly to constitute 
the ventricular (neuroepithelial) layer [9, 11]. In our 
study, moderate PAX2 immunostaining was noted in 
the wall of the forming spinal cord during these early 
stages (Table 1). Throughout the following stages, 
Figure 4. Transverse sections of the spinal cord of human embryo at CS 16; A — ventricular layer; B — mantle layer; C — marginal layer;  
a. Expression of Pax2 in the ventricular, mantle and marginal layer; b. Negative control, where during processing primary antibody was omitted.
Figure 5. Transverse sections of the spinal cord of the human embryos at CS 18; a. Expression of Pax2 in ventricular layer of the dorsal part of 
the developing spinal cord (arrow); b. Expression of Pax2 in the ventral part of the developing spinal cord. Double arrows indicated the weaker 
expression of Pax2 in the ventricular layer.
276
Folia Morphol., 2014, Vol. 73, No. 3
Pax2 protein expression increased and staining was 
stronger during CS 16–20 compared to CS 10 (Table 1). 
Furthermore, some regional differences in Pax2 
staining were seen in these later stages (CS 16–20) 
where the wall of the forming spinal cord has diffe-
rentiated into the ventricular, mantle and marginal 
zones. Differences were noted in the staining intensity 
between the dorsal and ventral parts: in the dorsal 
part of the developing spinal cord, expression of 
Pax2 was seen in all three layers at CS 16–20, but in 
the ventral part, staining was weak in the ventricular 
layer and Pax2 protein expression was mainly seen in 
the mantle and marginal layers. Spatial differences 
in the expression of Pax2 in the forming spinal cord 
of human embryos have also been found by other 
researchers. Terzic et al. [19] determined Pax2 expres-
sion in human embryos at CS 17 in the outer parts 
of the ventricular zone of the developing spinal cord, 
Figure 6. Transverse section of the brain of human embryos at CS 12; a. Expression of Pax2 in the wall of the hindbrain (A) and midbrain (B); 
b. Expression of Pax2 in the wall of the forebrain (arrow); c. Higher maginification of the wall of the forebrain from panel b.
Figure 7. Transverse section of the isthmus region in human brain at CS 20; a. Strong expression of Pax2; b. Negative control, where during 
processing primary antibody was omitted.
Figure 8. Transverse section of the brain of human embryos at CS 18; a. Expression of Pax2 in the wall of the diencephalon (arrows);  
b. Expression of Pax2 in the (A) ventricular, (B) mantle, and (C) marginal layers of the cerebellar plate.
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while Pax2 signal was missing in the ventral quarter 
of the ventricular zone. More extensive reaction was 
also described in the dorsolateral plates than in the 
ventrolateral plates [19]. Tellier et al. [18] detected 
Pax2 expression in the dorsal part of the germinati-
ve zone in human embryos of CS 14–18, and some 
cells of the alar plate, but not in the forming anterior 
horn. Spatially restricted expression of Pax2 in the 
developing spinal cord has also been demonstrated 
in studies on mice [10] and chickens [2]. Thus, accor-
ding to these findings, Pax2 can be considered one 
of the key regulators in the combinatorial action of 
transcription factors which determine the fate of 
specific populations of early neurons. 
In our study, Pax2 protein expression was also 
found in all the 3 brain vesicles, prosencephalon 
(forebrain), mesencephalon (midbrain) and rhom-
bencephalon (hindbrain). In early stages, CS 10–14, 
Pax2 staining in brain vesicles was relatively strong, 
especially when compared to that seen in the deve-
loping spinal cord in the same young embryos. The 
most significant difference was noted at the earliest 
stage — CS 10 (Table 1). However, at later stages, CS 
16–20, the strongest Pax2 expression was found at the 
junction of the midbrain and the hindbrain (Fig. 6a). 
This is in concordance with studies on chicken and 
mice embryos, where early expression of Pax2 has 
been detected in the mesencephalon and the anterior 
hindbrain, but subsequently Pax2 expression was 
restricted to the mid-hindbrain region [1, 14, 23]. 
In human embryos from day 32 to 50 (CS 14–19), 
Pax2 signal has been detected in the hindbrain, but 
not in the midbrain or the forebrain [18]. In studies 
on human 8-week embryos (CS 22), Terzic et al. [19] 
have shown Pax2 expression to extend from the me-
sencephalic-rhombencephalic border along the entire 
rhombencephalon. In particular, strong expression 
was detected in the outer part of the ventricular zone 
at the junction of the caudal mesencephalon and ro-
stral rhombencephalon [19]. This region is known as 
an isthmic organiser centre, which is believed to play 
an important role in the development of the mesen-
cephalon and the cerebellum [8]. Several experimental 
animal studies have suggested that initiation and fun-
ctioning of this organising centre crucially depends on 
Pax2 [1, 16, 22, 23], and that the regulatory role of 
Pax2 is an evolutionarily conserved feature for all ver-
tebrates [14]. Furthermore, it has been shown that a 
mutation of the Pax2 gene in the isthmus leads to the 
loss of the midbrain and the cerebellum [3, 15, 22]. 
In our study, Pax2 was also determined in the deve-
loping cerebellum and diencephalon. Expression of 
Pax2 was seen in the ventricular, mantle and mar-
ginal layers in the developing cerebellar plate. In 
mouse embryos, Pax2 has specifically been found to 
be expressed in a subset of GABAergic cells, and it is 
proposed that these cells are migratory precursors of 
the molecular layer interneurons (basket and stellate 
cells) [7]. The diencephalon, which develops from the 
median part of the forebrain, is thought to consist of 
a roof plate and 2 alar (dorsal) plates but to lack floor 
and basal (ventral) plates [9, 11]. Expression of Pax2 
in our study was found mostly in outer regions of the 
alar plates of the diencephalon. In mouse embryos, 
Pax2 expression has been determined in diencephalic 
cells at the border of region between diencephalon 
and telencephalon, more specifically in populations 
of cells within the developing septum, hypothalamus 
and eminentia thalami [4]. Furthermore, in mice, 
Pax2 has been shown to play an important role in 
the formation of the optic cup, which develops as an 
outgrowth of the diencephalon wall and therefore 
represents a direct extension of the brain tissue [4, 10, 
12]. Expression of Pax2 in the developing optic cup 
has also been detected in human embryos [18, 19]. 
Thus, it can be suggested that, in human neurogene-
sis, Pax2 is associated with the establishment of the 
developing diencephalon as well with the migration 
and determining cells in the alar plates. 
CONCLUSIONS
In conclusion, Pax2 protein expression in the de-
veloping spinal cord and brain of the human embryos 
mostly resembles descriptions of the role of Pax2 in 
the neurogenesis of animals where Pax2 is associated 
with the establishment of craniocaudal and ventro-
dorsal boundaries within the developing neural tube 
and with migration of specific neural cell populations. 
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